agenda

COVERING ALL THE IMPORTANT TOPICS

 
 

Amsterdam, 5 - 6 March 2025

Schedule

Create your personal agenda –check the favourite icon

Mar 57:30
Conference pass

Exhibitor Badge Collection

Keynotes

Exhibitor Badge Collection

Mar 58:00
Conference pass

Registration & Networking Meetings

Keynotes

Registration & Networking Meetings

Mar 58:55
Conference pass

Chair's Remarks

Keynotes

Chair's Remarks

Annette Powers, Senior Vice President, Global Market Access, Bristol Myers Squibb
Mar 59:00
Conference pass

Keynote presentation

Keynotes

Keynote presentation

Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Mar 59:20
Conference pass

Title Sponsor Keynote Presentation

Keynotes

Session reserved for Title Sponsor

Mar 59:40
Conference pass

Pathways to overcoming access barriers in LMICs

Keynotes
Claus Runge, Senior Vice President, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Mar 510:00
Conference pass

Keynote Sponsor Presentation - Lifescience Dynamics

Keynotes

Session Reserved for LIfescience Dynamics

Mar 510:20
Conference pass

Trends and opportunities in achieving health equity from the Access to Medicine Index

Keynotes
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Mar 510:40
Conference pass

Morning Break

Keynotes

Morning Break in Exhibition Hall

Mar 511:00
Conference pass

Morning Break & Poster Sessions

Keynotes

Poster sessions in exhibition hall

Mar 511:40
Conference pass

Chair's Remarks

Real World Evidence & Data
Shuvayu Sen, Vice President, Head of Oncology, Center of Observational & Real-World Evidence, Merck & Co., Inc.
Mar 511:40
Conference pass

Chair's Remarks

Market Access
Reg Waldeck, Vice President, Oncology Market Access Strategy Leader, Bayer
Mar 511:40
Conference pass

Chair's Remarks

Pricing
Marina Faiella, Independent Market Access Expert
Mar 511:40
Conference pass

Chair's Remarks

Pre-Launch Success
Gina Ewy, VP Global Market Access, Hansa Biopharma
Mar 511:40
Conference pass

Chair's Remarks

Reimbursement
Laurene Redding, Global Head, Value, Access & Pricing, BeiGene
Mar 511:40
Conference pass

Chair's Remarks

Rare Diseases
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Mar 511:40
Conference pass

Chair's Remarks

Digital Transformation
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, Astrazeneca
Mar 511:40
Conference pass

Chair's Remarks

HTA
Marlene Gyldmark, Vice President, Head, Global Access Evidence, Idorsia
Mar 511:40
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Marlene Gyldmark, Vice President, Head, Global Access Evidence, Idorsia
Mar 511:45
Conference pass

Evidence generation in support of health equity

Real World Evidence & Data
Kinga Borsos, Vice President, Head of US HEOR, Boehringer Ingelheim
Mar 511:45
Conference pass

Evaluating value of medicines through carbon footprint avoidance in the patient treatment pathway

Market Access
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Mar 511:45
Conference pass

Pricing innovations: art versus science

Pricing
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Mar 511:45
Conference pass

Optimising long term launch commercial success with indication sequencing

Pre-Launch Success
Mar 511:45
Conference pass

The dilemma between costly products for low populations versus wider reimbursement for low budget impact

Reimbursement
Tomer Benzaken, Director, Head of Commercial Operations & Trade, Astellas
Mar 511:45
Conference pass

International access needs for orphan drugs: improving evidence and pricing strategies

Rare Diseases
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Mar 511:45
Conference pass

Generative AI applications in market access and HEOR

Digital Transformation
Bill Malcolm, Executive Director, Global HEOR Economic & Predictive Modelling, BMS
Mar 511:45
Conference pass

SUSTAIN-HTA innovative methodologies: advancing national and European HTA practice

HTA
Mar 511:45
Conference pass

Improving gender disparities: advancing global health equity

Health Economics & Outcomes Research
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 512:05
Conference pass

Sponsor presentation

Real World Evidence & Data

Reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for EVERSANA

Market Access

Session reserved for sponsor

Mar 512:05
Conference pass

Sponsor presentation

Pricing

Session reserved for sponsor

Mar 512:05
Conference pass

Sponsor presentation

Pre-Launch Success

Session reserved for sponsor

Mar 512:05
Conference pass

Sponsor presentation

Reimbursement

Session reserved for sponsor

Mar 512:05
Conference pass

Sponsor presentation

Rare Diseases

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Stratence Partners

Digital Transformation

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Remap

HTA

Session reserved for sponsor

Mar 512:05
Conference pass

Session Reserved for Initiate

Health Economics & Outcomes Research

Session reserved for sponsor

Mar 512:25
Conference pass

RWE studies within registries: feasible or not?

Real World Evidence & Data
Helene Chevrou-Severac, Senior Director, RWE & Outcomes Centre of Excellence Head, Alexion – AstraZeneca Rare Disease
Mar 512:25
Conference pass

Novel medicines platform: what does this mean for EU access policy?

Market Access
Matt Slabbert, Vice President, Global Head of Pharma Public Affairs, Bayer
Mar 512:25
Conference pass

Challenges of international reference pricing

Pricing
Walmon Leal, Vice President, Head of Global Pricing, Tenders & Contract, Viatris
Mar 512:25
Conference pass

Deconstructing launches: learnings from mistakes and what works

Pre-Launch Success
Nidhi Dani, Director, Global Market Access, GSK
Mar 512:25
Conference pass

Improving access to innovative treatments across regions

Reimbursement
Fabian Schmidt, Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases
Mar 512:25
Conference pass

Expectations for collaborations between patient groups and industry in appraisal processes

Rare Diseases
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Mar 512:25
Conference pass

Where are we in AI for market access?

Digital Transformation
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck Group
Mar 512:25
Conference pass

Evidence and appraisal developments within HTA organisations: engaging stakeholders and policy makers

HTA
Goedele van Haasteren, Deputy Chief of the HTA department, Federal Office of Public Health, Switzerland
Mar 512:25
Conference pass

Improving HTA disparities for Middle East and North Africa

Health Economics & Outcomes Research
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Mar 512:45
Conference pass

Session Reserved for Genesis Research

Real World Evidence & Data

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Decisive Consulting

Market Access

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Precision Advisors

Pricing

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Stratenym

Pre-Launch Success

Session reserved for sponsor

Mar 512:45
Conference pass

Sponsor presentation

Reimbursement

Session reserved for sponsor

Mar 512:45
Conference pass

Sponsor presentation

Rare Diseases

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Global Pricing Innovations

Digital Transformation

Session reserved for sponsor

Mar 512:45
Conference pass

Session Reserved for Visible Analytics

HTA

Session reserved for sponsor

Mar 512:45
Conference pass

Sponsor presentation

Health Economics & Outcomes Research

Session reserved for sponsor

Mar 513:05
Conference pass

Lunch

Keynotes

Lunch in Exhibition Hall

Mar 514:30
Conference pass

01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence

Real World Evidence & Data
BauabwicklungskontoSteinkaut KreuznachDr Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer-Ingelheim
Seema Sondhi, Head, Payer Value & Access, Takeda
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Mar 514:30
Conference pass

01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence

Real World Evidence & Data
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Seema Sondhi, Head, Payer Value & Access, Takeda
Mar 514:30
Conference pass

02 Market Access Panel – Anticipated impacts of the EU HTA on market access

Market Access
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Marie Sanderson, Head of Value and Access, Innovative Medicine, Novartis
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, UCB
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Patrick Hopkinson, Vice President, GHEOR, International Markets and HTA Strategy, Bristol-Myers Squibb
Mar 514:30
Conference pass

03 Pricing Panel - Reserved by Inbeeo

Pricing

Session reserved by Inbeeo

Mar 514:30
Conference pass

04 Market Access Panel – Challenges and opportunities for access to innovation in LMICs

Pre-Launch Success
Korab Zuka, Vice President, Corporate Affairs, Purpose Communications and ESG, Bristol Myers Squibb
Pauline L'Hénaff, Head of Industry Engagement, Access to Medicine Foundation
Mathieu Gilbert, Chief Operating Officer, Adocia
Jorge Arellano, Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb
Diana Sinkevich, Head of Access, EU & International, Global Rare Diseases, Chiesi
Mar 514:30
Conference pass

05 Reimbursement Panel – The UK subscription model for antimicrobials: what’s next internationally?

Reimbursement
Warren Cowell, Director, Market Access UK, Shionogi Ltd
Janek Hendrich, Value Strategies Lead, Oncology, AstraZeneca
Mar 514:30
Conference pass

06 Rare Diseases Panel – Breaking down barriers for rare disease access: stakeholder perspectives

Rare Diseases
Luigi Angelillo, Director, Market Access EMEA, Argenx
Lorenzo Capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Philippe Ghyssels, Vice President, Global Public Affairs, Ipsen
Giovanni Tafuri, Director, EU Market Access and Policy, Apellis Pharmaceuticals
Mar 514:30
Conference pass

07 Digital Transformation Panel – Patient-sourced data to accelerate digital transformation

Digital Transformation
Dawn Ireland, President & Founder, CDH International
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 514:30
Conference pass

08 HTA Panel – Challenges for the implementation of the EU HTA

HTA
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Gergana Zlateva, Vice President, Global Access & Pricing, Oncology, Pfizer
Josep M Guiu, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Eelko Den Breejen, Sr. Director. Global Access Strategy & Pricing Oncology Team Lead. Portfolio & Market Engagement, Pfizer
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Mar 514:30
Conference pass

09 Health Economics & Outcomes Research Panel – Parexel

Health Economics & Outcomes Research

Session reserved for sponsor

Mar 515:30
Conference pass

Chair's Remarks

Real World Evidence & Data
Tristan Gloede, Executive Director, Global Head of Market Access Retinal Health, Boehringer Ingelheim
Mar 515:30
Conference pass

Chair's Remarks

Market Access
Don Creighton, Executive Director, Market Access Pipeline and Readiness Lead, Regeneron
Mar 515:30
Conference pass

Chair's Remarks

Pricing
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic
Mar 515:30
Conference pass

Chair's Remarks

Pre-Launch Success
Julie Powell, Director, Patient Advocacy and Public Affairs, Pleco Therapeutics
Mar 515:30
Conference pass

Chair's Remarks

Reimbursement
Lisette Kaskens, Director Market Access, Ferring Pharmaceuticals
Mar 515:30
Conference pass

Chair's Remarks

Rare Diseases
Tomaso Piaggio, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Mar 515:30
Conference pass

Chair's Remarks

Digital Transformation
Florence Robson-Barkats, Head of Patient Engagement, NHS Improvement
Mar 515:30
Conference pass

Chair's Remarks

HTA
Marnix Artz, Head, Patient Access, Pricing & Governmental Affairs, Merck Group
Mar 515:30
Conference pass

Chair's Remarks

Health Economics & Outcomes Research

Chair's Remarks

Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Mar 515:35
Conference pass

Evidence generation for HTA submissions

Real World Evidence & Data
Patricia Dorling, Vice President, Head, Global HEOR and Real World Evidence, Chiesi Group
Mar 515:35
Conference pass

Leading an innovative culture in access teams

Market Access
Robert Palmer, Head of Access, Oncology, Boehringer Ingelheim
Mar 515:35
Conference pass

Developing fair pricing to increase rare disease access in emerging countries

Pricing
Philippe Mourouga, Vice President, International Partner Markets, Biogen
Mar 515:35
Conference pass

The good, the bad and the ugly of launches: case studies and outcomes

Pre-Launch Success
Hannah Kurth, Founder and Managing Director, Pulse Edge
Mar 515:35
Conference pass

Leveraging current reimbursement pathways to enable more equitable access for antibiotics

Reimbursement
Jennifer Quinn, Head of Global Value and Access, Debiopharm International
Mar 515:35
Conference pass

Enabling earlier access for rare diseases: evaluating evidence for orphan drugs and payer challenges

Rare Diseases
Eunice Alvazzi, Head of Global Value & Access, Hematology, Nephrology & Neurology,, Alexion – AstraZeneca Rare Disease
Mar 515:35
Conference pass

AI in the service of digital transformation

Digital Transformation
Angie Kehagia, Deputy Director, Senior HTA, KiTEC King's Technology Evaluation Centre
Mar 515:35
Conference pass

How have HTA agencies evolved their methods over time? The importance of understanding HTA reforms

HTA
Martina Garau, Director, Office of Health Economics
Mar 515:35
Conference pass

From data to access: unlocking the patient journey

Health Economics & Outcomes Research
Thilo Schaufler, Global Head, Health Economics and Outcomes Research, CSL Vifor
Mar 515:55
Conference pass

Sponsor presentation

Real World Evidence & Data

Reserved for sponsor

Mar 515:55
Conference pass

Session reserved for Access Infinity

Market Access

Reserved for Access Infinity

Mar 515:55
Conference pass

Session Reserved for RxData

Pricing

Reserved for RxData

Mar 515:55
Conference pass

Session reserved for PDCI

Pre-Launch Success

Reserved for PDCI

Mar 515:55
Conference pass

Sponsor presentation

Reimbursement

Reserved for sponsor

Mar 515:55
Conference pass

Session Reserved for Pharma Business Partners

Rare Diseases

Reserved for Pharma Business Partners

Mar 515:55
Conference pass

Session Reserved for IQVIA

Digital Transformation

Reserved for IQVIA

Mar 515:55
Conference pass

Sponsor presentation

HTA

Reserved for sponsor

Mar 515:55
Conference pass

Sponsor presentation

HTA

Reserved for Sponsor

Mar 515:55
Conference pass

Sponsor presentation

Health Economics & Outcomes Research

Reserved for sponsor

Mar 516:15
Conference pass

RWE to support patient access: inequity of access across Denmark

Real World Evidence & Data
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Mar 516:15
Conference pass

Augmenting patient access through technology: democratising digital tools for market access

Market Access
Vijay Reddy, Chief Commercial Officer, Avinya Biotech
Mar 516:15
Conference pass

Pricing challenges and changing mindsets for high cost therapies

Pricing
Lara Pippo, Head of Market Access & Government Affairs, Italy, CSL Behring
Mar 516:15
Conference pass

Subnational reimbursement strategies for successful launches

Pre-Launch Success
Johnny Bane, Head of Market Access, Accord Healthcare
Mar 516:15
Conference pass

Advancing precision oncology across Europe: challenges for funding and reimbursement

Reimbursement
Matthijs Van Meerveld, Associate Vice President, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
Mar 516:15
Conference pass

Enhancing collaborations with industry: improving patient ac-cess early in the development cycle

Rare Diseases
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 516:15
Conference pass

Developing blockchain platforms for real world evidence generation in small population studies

Digital Transformation
Mar 516:15
Conference pass

Cost effectiveness and early access arrangements

HTA
Hans Severens, Independent HTA Expert, Severens HTA Consultancy
Mar 516:15
Conference pass

Societal perspectives in cost effectiveness analyses: a comprehensive assessment

Health Economics & Outcomes Research
Matthias Bischof, Senior Director, International Health Economics, Novartis
Mar 516:35
Conference pass

Networking Break

Keynotes

Networking break in exhibition hall

Mar 517:20
Conference pass

Chair's Remarks

Real World Evidence & Data

Chair's remarks

Mar 517:20
Conference pass

Chair's Remarks

Market Access
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 517:20
Conference pass

Chair's Remarks

Pricing

Chair's Remarks

Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Mar 517:20
Conference pass
Mar 517:20
Conference pass

Chair's Remarks

Reimbursement

Chair's Remarks

Manuela Machado, Global Payer Strategy Solutions Lead, UCB
Mar 517:20
Conference pass

Chair's Remarks

Rare Diseases
Loubna Ouriaghli, Head of Government Affairs and Policy, Ipsen
Mar 517:20
Conference pass

Chair's Remarks

Digital Transformation

Chair's Remarks

Mar 517:20
Conference pass

Chair's Remarks

HTA

Chair's Remarks

Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Mar 517:20
Conference pass

Chair's Remarks

Health Economics & Outcomes Research

Chair's Remarks

Mar 517:25
Conference pass

Sponsor presentation

Real World Evidence & Data

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Market Access

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Pricing

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Pre-Launch Success

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Reimbursement

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Rare Diseases

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Digital Transformation

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Digital Transformation

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

HTA

Reserved for sponsor

Mar 517:25
Conference pass

Sponsor presentation

Health Economics & Outcomes Research

Reserved for sponsor

Mar 517:45
Conference pass

Risk aversion and health insurance: long terms perspectives on thresholds for real world evidence

Real World Evidence & Data
JÖRG MAHLICH, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Mar 517:45
Conference pass

Early access programs: Italian experiences

Market Access
Silvia Miriam CAMMARATA, Senior Regulatory Affairs and Health Policy Specialist, AIFA Italian Medicine Agency
Mar 517:45
Conference pass

Challenges and opportunities for multi-indication pricing

Pricing
Julien Patris, Head of Patient Advocacy, Public Policy, Corporate Communications, EMEA, arGEN-X
Mar 517:45
Conference pass

Elevating market access to enable successful launches

Pre-Launch Success
Najib Slassi, Director, Global Product Strategy, Novartis
Mar 517:45
Conference pass

Reimbursement and negotiating access to orphan medications: regulatory and policy hurdles

Reimbursement
Mar 517:45
Conference pass

A global call to action for rare diseases

Rare Diseases
Jan Swiderski, Director, Head of Global Public Affairs and Advocacy, Ipsen
Philippe Ghyssels, Vice President, Global Public Affairs, Ipsen
Mar 517:45
Conference pass

Speaker presentation

Digital Transformation

Speaker presentation

Mar 517:45
Conference pass

HTA of artificial intelligence: special considerations and development of a checklist

HTA

Speaker presentation

Antonia Needham-Taylor, Health Services Researcher, Health Technology Wales
Mar 517:45
Conference pass

Speaker presentation

Health Economics & Outcomes Research

Speaker presentation

Mar 518:05
Conference pass

Close of conference and drinks reception

Keynotes

Drink reception in exhibition hall

Create your personal agenda –check the favourite icon

Mar 68:55
Conference pass

Chair's Remarks

Keynotes

Keynote session

Mar 69:00
Conference pass
Mar 69:20
Conference pass

Keynote presentation - Parexel

Keynotes

Keynote presentation - Parexel

Mar 69:40
Conference pass

Environmental sustainability and access to medicines – the way forward

Keynotes
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Mar 610:00
Conference pass

Keynote presentation - Valid Insight

Keynotes

Keynote presentation - Valid Insight

Mar 610:20
Conference pass

Keynote panel discussion: Global healthcare reforms and their implications on local market access strategy

Keynotes
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Portfolio Strategy, Access & Pricing, Novo Nordisk A/S
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Mar 610:20
Conference pass

Keynote panel discussion: Global healthcare reforms and their implications on local market access strategy

Keynotes
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Portfolio Strategy, Access & Pricing, Novo Nordisk A/S
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Mar 611:55
Conference pass

Chair's Remarks

Real World Evidence & Data
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Mar 611:55
Conference pass

Chair's Remarks

Market Access
Lucia Paone, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Mar 611:55
Conference pass

Chair's Remarks

Pricing
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Mar 611:55
Conference pass

Chair's Remarks

Pre-Launch Success
Ana Filipa Alexandre, Market Access, Value Outcomes and RWE Consultant, Keys2Access
Mar 611:55
Conference pass
Mar 611:55
Conference pass

Chair's Remarks

Rare Diseases
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 611:55
Conference pass

Chair's Remarks

Digital Transformation

Chair's Remarks

Mar 611:55
Conference pass

Chair's Remarks - Reserved, Norwegian Medical Products Agency

HTA

Reserved for Norwegian Medical Products Agency

Mar 611:55
Conference pass
Mar 612:00
Conference pass

Developing RWE platforms: allowing for high quality execution of evidence generation

Real World Evidence & Data
Tom Burke, Scientific Associate Vice President, CORE, MSD
Mar 612:00
Conference pass

Recent payer perspectives on novel end points

Market Access
Marie-Sharmila Blandino, Global Access Strategy Lead, Amgen
Mar 612:00
Conference pass

Early decision making for innovative medicine pricing

Pricing
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 612:00
Conference pass

Providing frameworks, incentives and tools to enable successful product development

Pre-Launch Success
Gorana Capkun, Vice President, Global Head of Patient Focused Real World Evidence, Merck Group
Mar 612:00
Conference pass

Innovative reimbursement schemes: uncertainties and performance indicators

Reimbursement
Ad Antonisse, Director, Market Access & Corporate Affairs, Astrazeneca
Mar 612:00
Conference pass

Bringing in patient voices to health authorities and industry

Rare Diseases
Sofiya Got, Strategy and Transformation Analyst, NHS
Mar 612:00
Conference pass

Developing new HTA frameworks and methodologies for digital health technologies: the EDiHTA project

Digital Transformation
Wija Oortwijn, Chair of Appraisal Committee at ZINL & Assistant Professor, HTA, ZIN & Radboud University Medical Center
Emmanouil Tsiasiotis, Research Project Manager and Coordinator, EDiHTA
Mar 612:00
Conference pass

Decisional framework to accelerate integration of valuable innovations

HTA
Michele de Guise, President and Chief Executive Officer, INESSS
Mar 612:00
Conference pass

Simplifying targeted patient support to improve treatment outcomes and cost-effectiveness

Health Economics & Outcomes Research
Claire Everitt, Design Engineering Team Lead, IMI Project Leader, Pfizer
Mar 612:20
Conference pass

Sponsor presentation

Real World Evidence & Data

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Market Access

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Pricing

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Pre-Launch Success

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Reimbursement

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Rare Diseases

Reserved for sponsor

Mar 612:20
Conference pass

Sponsor presentation

Digital Transformation

Reserved for Sponsor

Mar 612:20
Conference pass

Sponsor presentation

HTA

Reserved for sponsor

Mar 612:20
Conference pass

Chair's Remarks

Health Economics & Outcomes Research

Chair's Remarks

Mar 612:40
Conference pass

Impacts of integrated evidence approaches: measuring KPIs and patient benefits

Real World Evidence & Data
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Mar 612:40
Conference pass

Applicability and generalizability of US community oncology EHR data to support robust global evidence dossiers

Market Access
Casey Rhode, Senior Vice President, Corporate Strategy, OneOncology
Mar 612:40
Conference pass

Implications of crossborder collaborations for pricing and procurement

Pricing
Neil Grubert, Global Market Access Expert, Independent
Mar 612:40
Conference pass

Deconstructing launches: learnings from patient journeys in rare diseases

Pre-Launch Success
Marianne Laouri, Executive Director, Global Asset Lead, Retinal Health, Boehringer Ingelheim
Mar 612:40
Conference pass

Translating clinical evidence to building pricing and reimbursement negotiation strategies: neuroeconomic approaches

Reimbursement
Mar 612:40
Conference pass

Drug-device combination products for orphan diseases: dealing with unmet needs and data uncertainty

Rare Diseases
Lotta Parviainen, Head of Global Market Access, Zambon France
Mar 612:40
Conference pass

Omni channel approaches to improve customer interactions through digital and other pathways

Digital Transformation
Aodan Tynan, Vice President, Global Market Access, Astellas
Mar 612:40
Conference pass

Speaker presentation for NICE

HTA

Reserved for NICE

Mar 612:40
Conference pass

The value of investing in healthcare systems for the future

Health Economics & Outcomes Research

Speaker presentation

Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Johnson & Johnson Innovative Medicine
Mar 613:00
Conference pass

RWE: when does it move the needle?

Real World Evidence & Data

Reserved for sponsor

Geraldine Rylander, Director, Global Market Access, Psychiatry & Pipeline, Lundbeck
Mar 613:00
Conference pass

Session Reserved for LCP

Market Access

Reserved for LCP

Mar 613:00
Conference pass

Session Reserved for Stratence Partners

Pricing

Session Reserved for Stratence Partners

Mar 613:00
Conference pass

Session Reserved for AMICULUM

Pre-Launch Success

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Reimbursement

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Rare Diseases

Reserved for sponsor

Mar 613:00
Conference pass

Sponsor presentation

Digital Transformation

Reserved for sponsor

Mar 613:00
Conference pass

Session Reserved for AESARA

HTA

Reserved for AESARA

Mar 613:00
Conference pass

Sponsor presentation

Health Economics & Outcomes Research

Reserved for sponsor

Mar 613:20
Conference pass

Lunch

Keynotes

Lunch in exhibition hall

Mar 614:45
Conference pass

01 Real World Evidence & Data Panel – From data to decisions: harnessing evidence for seamless product launches

Real World Evidence & Data
Sylvie Greneche, Head of Global Market Access, General Medicines, Sanofi
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Mar 614:45
Conference pass

02 Market Access Panel – Improving access to gene therapies: challenges and key learnings

Market Access
Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Dilip Patel, SVP, Pricing, Value & Access Strategy, Autolus
Loic Gauthier, Director, Market Access and Pricing, Intercontinental Region, CSL Behring
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Stephen Connell, Senior Director, Global Pricing & Market Access - Gene Therapy, Pfizer
Mar 614:45
Conference pass

03 Pricing Panel – Value based healthcare in theory and practice: challenges for pricing

Pricing
Chris Prins, Policy Advisor Expensive Medicines, Zorgverzekeraars Nederland
Emanuele Degortes, Vice President, Global Head of Access Policy and Patient Advocacy, Menarini
Igor Solev, Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories
Jose Aragunde, Value and Pricing Strategy Lead, Market Access, Novartis
Clare Jamookeeah, Global Director, Global Value Strategies, Oncology Market Access, AstraZeneca
Mar 614:45
Conference pass

04 Pre-launch Success Panel – Access Infinity

Pre-Launch Success

Session Reserved for Access Infinity

Mar 614:45
Conference pass

04 Pre-launch Success Panel – Access Infinity

Pre-Launch Success

Session Reserved for Access Infinity

Mar 614:45
Conference pass

05 Reimbursement Panel – Sustainability of healthcare: reimbursement driven by affordability constraints

Reimbursement
Marta Andreykiv, Head of Market Access Europe, Viatris
Mary Lynne van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Daniel Jackson, Global Head, Market Access Policy, UCB
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Chiara Brouns, Strategic purchaser, Zorgverzekeraars Nederland
Mar 614:45
Conference pass

06 Rare Diseases Panel – Delivering pharmaceutical innovation across the globe: WHO Europe & the Novel Medicines Platform

Rare Diseases
Antonella Cardone, CEO, Cancer Patients Europe
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Jean Christophe Goirand, Senior Director, Global Head Market Access & Pricing, Essential Pharma
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Mar 614:45
Conference pass

07 Digital Transformation Panel - Reserved for sponsor

Digital Transformation

Reserved for sponsor

Mar 614:45
Conference pass

08 HTA Panel – Rethinking added values of AI in HTA: debunking myths

HTA
Dalia Dawoud, Associate Director, Research, NICE
Mar 614:45
Conference pass

09 Health Economics & Outcomes Research Panel – What are the next steps for generative AI in HEOR?

Health Economics & Outcomes Research
Alen Marijam, Senior Director, Vaccines, HEOR and Epidemiology Lead, Europe, GSK
Oresta Piniazhko, Director, Hta Department, Ministry of Health, Ukraine
Mar 615:45
Conference pass

Chair's Remarks

Real World Evidence & Data

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Market Access

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Pricing

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Pre-Launch Success

Chair's Remarks

Sandra Margunato-Debay, Senior Director, Global Market Access, Genmab
Mar 615:45
Conference pass

Chair's Remarks

Reimbursement

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Rare Diseases

Chair's Remarks

Sandra Nestler-Parr, Vice President, Value & Access, BioCryst Pharmaceuticals
Mar 615:45
Conference pass

Chair's Remarks

Digital Transformation

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

HTA

Chair's Remarks

Mar 615:45
Conference pass

Chair's Remarks

Health Economics & Outcomes Research

Chair's Remarks

Mar 615:50
Conference pass

Real-world evidence in Germany: challenges for industry

Real World Evidence & Data

Speaker presentation

Mar 615:50
Conference pass

Commercially sustainable access: expanding access in LMICs

Market Access

Speaker presentation

Mar 615:50
Conference pass

Speaker presentation

Pricing

Speaker presentation

Mar 615:50
Conference pass

Early development plans: determining scenarios for value and outcomes in Europe

Pre-Launch Success
Steven Flostrand, Executive Director, Value, Access & Pricing, Incyte Corp.
Mar 615:50
Conference pass

Reimbursement pathways in the Netherlands: creating dialogues between pharma, hospitals and payers

Reimbursement

Speaker presentation

Ellen Terwindt, Senior Market Access Manager, Gilead Sciences
Mar 615:50
Conference pass

Challenges and opportunities to launching two assets in one rare disease indication

Rare Diseases

Speaker presentation

Sebastian Kessel, Senior Director, Head of Market Access & Public Affairs, Germany, UCB
Mar 615:50
Conference pass

Speaker presentation

Digital Transformation

Speaker presentation

Mar 615:50
Conference pass

Title TBC

HTA

Speaker presentation

Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 615:50
Conference pass

PICO prediction using an AI-enabled tool

Health Economics & Outcomes Research

Speaker presentation

Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Mar 616:10
Conference pass

Sponsor presentation

Real World Evidence & Data

Reserved for sponsor

Mar 616:10
Conference pass

Session Reserved for IPSOS

Market Access

Reserved for IPSOS

Mar 616:10
Conference pass

Sponsor presentation

Pricing

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Pre-Launch Success

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Reimbursement

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Rare Diseases

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Digital Transformation

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

HTA

Reserved for sponsor

Mar 616:10
Conference pass

Sponsor presentation

Health Economics & Outcomes Research

Reserved for sponsor

Mar 616:30
Conference pass

Speaker presentation

Real World Evidence & Data

Speaker presentation

Mar 616:30
Conference pass

Market access in medical devices: a case study

Market Access
Samir Bhattacharyya, Global Vice President, Value Marketing, Health Economics & Market Access, Boston Scientific Corporation
Mar 616:30
Conference pass

Speaker presentation

Pricing

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Pre-Launch Success

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Reimbursement

Speaker presentation

Mar 616:30
Conference pass

Assessing the highly specialised technologies programme at NICE: case studies in two treatments for ultra rare diseases

Rare Diseases

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Digital Transformation

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

HTA

Speaker presentation

Mar 616:30
Conference pass

Speaker presentation

Health Economics & Outcomes Research

Speaker presentation

last published: 10/Sep/24 09:56 GMT
 
 

Get Involved 
 

Sponsorship & Exhibition Sales


David Boore 
david.boore@terrapinn.com
+44 20 8164 3052

Conference Production


George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940

Marketing Opportunities


Karen Duncan
karen.duncan@terrapinn.com